Suchergebnisse - "SUBKLEWE MARION"

PubPharm (10)

1

Combining venetoclax and azacytidine with T-cell bispecific antibodies for treatment of acute myeloid leukemia : a preclinical assessment

enthalten in: Leukemia | 2024

von Hänel, G. | Schönle, A. | Neumann, A. | +15

2

CD33 BiTE® molecule-mediated immune synapse formation and subsequent T-cell activation is determined by the expression profile of activating and inhibitory checkpoint molecules on AML cells

enthalten in: Cancer immunology, immunotherapy : CII | 2023

von Marcinek, A. | Brauchle, B. | Rohrbacher, L. | +13

ErratumIn: Cancer Immunol Immunother. 2023 May 8;:. - PMID 37154851

3

T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals

enthalten in: Blood | 2022

von Philipp, N. | Kazerani, M. | Nicholls, A. | +22

CommentIn: Blood. 2022 Sep 8;140(10):1056-1058. - PMID 36074532

4

Targeting intracellular WT1 in AML with a novel RMF-peptide-MHC-specific T-cell bispecific antibody

enthalten in: Blood | 2021

von Augsberger, C. | Hänel, G. | Xu, W. | +33

CommentIn: Blood. 2021 Dec 23;138(25):2598-2599. - PMID 34940819

5

Chimeric Antigen Receptor-Modified T Cells and T Cell-Engaging Bispecific Antibodies : Different Tools for the Same Job

enthalten in: Current hematologic malignancy reports | 2021

von Schwerdtfeger, M. | Benmebarek, M. | Endres, S. | +3

6

Characterization of a Novel FLT3 BiTE Molecule for the Treatment of Acute Myeloid Leukemia

enthalten in: Molecular cancer therapeutics | 2020

von Brauchle, B. | Goldstein, R. | Karbowski, C. | +23

7

The BiTE (bispecific T-cell engager) platform : Development and future potential of a targeted immuno-oncology therapy across tumor types

enthalten in: Cancer | 2020

von Einsele, H. | Borghaei, H. | Orlowski, R. | +6

8

Clinical overview of anti-CD19 BiTE(®) and ex vivo data from anti-CD33 BiTE(®) as examples for retargeting T cells in hematologic malignancies

enthalten in: Molecular immunology | 2015

von Zugmaier, G. | Klinger, M. | Schmidt, M. | +1

9

Increase of PD-L1 expressing B-precursor ALL cells in a patient resistant to the CD19/CD3-bispecific T cell engager antibody blinatumomab

enthalten in: Journal of hematology & oncology | 2015

von Köhnke, T. | Krupka, C. | Tischer, J. | +2

10

CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330

enthalten in: Blood | 2014

von Krupka, C. | Kufer, P. | Kischel, R. | +12

1
[1]